文献速递基础与转化研究临床试验与 GCP

基于单克隆抗体的阴道多用途预防膜剂(MB66)的安全性、可接受性与药代动力学:I期随机试验

Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial.
PubMed 文献 · PLoS Med · 2021-02-03

MB66膜是含抗HIV-1(VRC01-N)及抗HSV-1/2(HSV8-N)单克隆抗体的多用途预防技术产品,抗体经本氏烟草瞬时表达。I期试验评估单次和重复阴道给药的安全性、药代动力学及体外效力:产品总体安全耐受,无严重不良事件,用药后24小时阴道分泌物中两种抗体浓度显著升高并显著中和HIV-1和HSV-2。

要点

  • MB66膜单次及连续7天阴道给药安全耐受,无严重不良事件。
  • 用药后1小时抗体浓度达峰,24小时仍显著高于基线且远超IC50。
  • 用药后24小时宫颈阴道灌洗液显著中和HIV-1和HSV-2。

核心结论

  • 单次和重复阴道应用MB66膜安全、耐受良好且可接受。
  • 两种单抗在阴道分泌物中的浓度和体外生物活性显著升高,可能提供给药后至少24小时的保护。
  • 仍需在HIV和HSV感染风险女性中进一步评估MB66膜的效力。

研究设计与样本

  • I期临床试验,纳入健康育龄期、禁欲女性。
  • A段9名女性接受临床医生置入的单次MB66膜。
  • B段29名女性随机分配至MB66(活性)或安慰剂膜组,连续7天每日阴道置入1片。
  • 主要终点为与产品使用相关的2级及以上不良事件数量。

主要发现

  • 两段均未记录严重不良事件,不良事件主要为泌尿生殖系统,最常见为无症状镜下血尿。
  • 两段及活性组与安慰剂组间阴道pH或Nugent评分无差异,促炎细胞因子水平无显著升高。
  • 使用后调查判定产品可接受性和使用意愿高。
  • 活性膜给药后1小时抗体浓度达峰(中位数35 μg/mL),首次和第七次给药后24小时仍显著升高(中位数1.8 μg/mL)。
  • 校正样本稀释(1:20)后,24小时VRC01-N浓度为36至700 μg/mL,HSV8-N浓度为80至601 μg/mL。

关键数值与推荐

  • VRC01对HIV的IC50为0.32 μg/mL,24小时VRC01-N浓度超过其100倍以上。
  • HSV8-N的IC50为0.1 μg/mL,24小时浓度远高于该值。
  • MB66置入后24小时采集的CVL样本显著中和HIV-1和HSV-2。

临床怎么用

  • MB66膜可作为女性阴道使用的多用途预防技术产品,单次给药可能提供至少24小时保护。
  • 该平台可进一步添加抗体以预防其他性传播感染并提供避孕。

局限性

  • 研究队列规模小。
  • 未在24小时至7天之间采集药代动力学评估样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MB66 film is a multipurpose prevention technology (MPT) product with monoclonal antibodies (mAbs) against HIV-1 (VRC01-N) and HSV-1 and 2 (HSV8-N). The mAbs were produced by transient expression in Nicotiana benthamiana (N). We conducted a Phase I clinical trial to assess the safety, pharmacokinetics (PK), and ex vivo efficacy of single and repeated doses of MB66 when used intravaginally. METHODS AND FINDINGS: The clinical trial enrolled healthy reproductive-aged, sexually abstinent women. In Segment A, 9 women received a single MB66 film which was inserted into the vaginal posterior fornix by a clinician. In Segment B, 29 women were randomly assigned to MB66 (Active) or Placebo film groups and were instructed to insert 1 film vaginally for 7 consecutive days. Visits and clinical sampling occurred predose and at various time points after single and repeated film doses. The primary endpoint was number of adverse events (AEs) Grade 2 or higher related to product use. Secondary endpoints included film dissolution rate, Nugent score (a Gram stain scoring system to diagnose bacterial vaginosis), vaginal pH, post-use survey results, cytokine concentrations in cervicovaginal lavage (CVL) specimens (assessed by Luminex assay), mAb concentrations in vaginal fluid collected from 4 sites (assessed by ELISA), and HIV and HSV neutralization activity of CVL samples ex vivo (assessed by TZM-bl and plaque reduction assay, respectively). The product was generally safe and well tolerated, with no serious AEs recorded in either segment. The AEs in this study were primarily genitourinary in nature with the most commonly reported AE being asymptomatic microscopic hematuria. There were no differences in vaginal pH or Nugent scores or significant increases in levels of proinflammatory cytokines for up to 7 days after film insertion in either segment or between Active and Placebo groups. Acceptability and willingness to use the product were judged to be high by post-use surveys. Concentrations of VRC01-N and HSV8-N in vaginal secretions were assessed over time to generate pharmacokinetic curves. Antibody levels peaked 1 hour postdosing with Active film (median: 35 μg/mL) and remained significantly elevated at 24 hours post first and seventh film (median: 1.8 μg/mL). Correcting for sample dilution (1:20), VRC01-N concentrations ranged from 36 to 700 μg/mL at the 24-hour time point, greater than 100-fold the IC50 for VRC01 (0.32 μg/mL); HSV8-N concentrations ranged from 80 to 601 μg/mL, well above the IC50 of 0.1 μg/m. CVL samples collected 24 hours after MB66 insertion significantly neutralized both HIV-1 and HSV-2 ex vivo. Study limitations include the small size of the study cohort, and the fact that no samples were collected between 24 hours and 7 days for pharmacokinetic evaluation. CONCLUSIONS: Single and repeated intravaginal applications of MB66 film were safe, well tolerated, and acceptable. Concentrations and ex vivo bioactivity of both mAbs in vaginal secretions were significantly elevated and thus could provide protection for at least 24 hours postdose. However, further research is needed to evaluate the efficacy of MB66 film in women at risk for HIV and HSV infection. Additional antibodies could be added to this platform to provide protection against other sexually transmitted infections (STIs) and contraception. TRIAL REGISTRATION: ClinicalTrials.gov NCT02579083.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Politch JA, Cu-Uvin S, Moench TR, et al. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial. PLoS Med. 2021. PMID: 33534791. doi:10.1371/journal.pmed.1003495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。